5 years ago

Wren Therapeutics Raises £12.4M to Develop Novel Drugs for Alzheimer's and Parkinson's

  • Cambridge-based biotech startup Wren Therapeutics has raised £12.4 million in Series A funding to advance its novel drug discovery platform for protein misfolding diseases

  • The company, a spin-off from the University of Cambridge and Lund University, will use the funds to accelerate its lead programs for Alzheimer's and Parkinson's diseases

  • Wren's unique approach maps and modulates the chemical kinetics of misfolding proteins, aiming to create transformative treatments for millions of patients globally.

      • ProblemHealthcare

      "Millions of people globally suffer from protein misfolding diseases like Alzheimer's and Parkinson's disease, type-2 diabetes, and many rare forms of amyloidosis. Current treatments are limited and there is a need for new therapies that can effectively target these diseases."

      Solution

      "Wren Therapeutics is developing a unique approach to drug discovery for protein misfolding diseases. Their platform allows them to map and selectively modulate the complex chemical kinetic networks associated with misfolding proteins, leading to the development of novel therapeutics. This approach has the potential to create transformative treatment options for patients suffering from these debilitating diseases."

      Covered on